ValenTx gins $22M Series B; Academics earn up to $110K from industry;

> Carpinteria, CA-based ValenTx says it's closed on a $22 million Series B to back the development of a less-invasive device to control obesity. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company`s existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures. ValenTx release

> Protalix has won orphan drug status for its Gaucher's drug. Story

> Australia's Bionomics has raised $15 million for the clinical development of two experimental therapies. Article

> Debiopharm has won an exclusive worldwide license to develop and commercialize Ipsen's CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers. Release

> Salix won marketing approval for Metozolv ODT, a therapy indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy. Salix release

Pharma News

> Anti-AIDS activists are calling on GlaxoSmithKline to contribute its HIV-related intellectual property to a patent pool. Article

> In the wake of last week's $2.3 billion settlement between Pfizer and the U.S. government, experts are looking at that enormous price tag--and finding not much of a deterrent, the Associated Press reports. Article

> A slew of new H1N1 flu treatment news hit over the long weekend, so we're offering a roundup to help you get back up to speed. Article

Biotech IT News

> Virginia Tech has begun a scale-up of its GenoCAD synthetic biology software, used in designing genetic constructs. The effort stems from a $1.4 million grant from the National Science Foundation, thanks to stimulus package funding. Article

> Personal PCR--polymerase chain reaction technology in a machine that costs a fraction of the tens of thousands of dollars of current technology--may be right around the corner. Article

> Ten screening libraries from ChemBridge are now available to researchers via the Collaborative Drug Discovery (CDD) public access database. Article

And Finally... Researchers at U.S. universities garner an average of a little more than $33,000 a year from the drug and device industry, with some earning up to $110,869, according to a new survey of 1,663 researchers. And those lucrative and very common ties are raising the importance of revealing the financial links that bind academic researchers to industry. Article

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.